Cetuximab in the management of nasopharyngeal carcinoma - A narrative review

M. S. Iqbal, D. Wilkinson, A. Tin, P. Bossi, L. Gradwell-Nelson, J. Kovarik, J. O'Hara, C. Kelly

Research output: Contribution to journalReview article

Abstract

BackgroundConcurrent chemotherapy with radiotherapy is the standard treatment for locoregionally advanced nasopharyngeal cancer. Cetuximab can be used in the treatment of head and neck squamous cell carcinoma. However, the randomised studies that led to approval for its use in this setting excluded nasopharyngeal cancer. In the context of limited data for the use of cetuximab in nasopharyngeal cancer in the medical literature, this review aimed to summarise the current evidence for its use in both primary and recurrent or metastatic disease.MethodA literature search was performed using the keywords 'nasopharyngeal neoplasm', 'cetuximab' and 'Erbitux'.ResultsTwenty studies were included. There were no randomised phase III trials, but there were nine phase II trials. The use of cetuximab in the treatment of nasopharyngeal carcinoma has been tested in various settings, including in combination with induction chemotherapy and concurrent chemoradiotherapy, and in the palliative setting.ConclusionThere is no evidence of benefit from the addition of cetuximab to standard management protocols, and there is some evidence of increased toxicity. There is more promise for its use in metastatic or locally recurrent settings. This review draws together the existing evidence and could provide a focus for future studies.

Original languageEnglish
JournalJournal of Laryngology and Otology
DOIs
Publication statusAccepted/In press - Jan 1 2019

Fingerprint

Nasopharyngeal Neoplasms
Induction Chemotherapy
Chemoradiotherapy
Cetuximab
Nasopharyngeal carcinoma
Radiotherapy
Therapeutics
Drug Therapy

Keywords

  • Cetuximab
  • Nasopharyngeal Carcinoma
  • Review

ASJC Scopus subject areas

  • Otorhinolaryngology

Cite this

Iqbal, M. S., Wilkinson, D., Tin, A., Bossi, P., Gradwell-Nelson, L., Kovarik, J., ... Kelly, C. (Accepted/In press). Cetuximab in the management of nasopharyngeal carcinoma - A narrative review. Journal of Laryngology and Otology. https://doi.org/10.1017/S0022215119001853

Cetuximab in the management of nasopharyngeal carcinoma - A narrative review. / Iqbal, M. S.; Wilkinson, D.; Tin, A.; Bossi, P.; Gradwell-Nelson, L.; Kovarik, J.; O'Hara, J.; Kelly, C.

In: Journal of Laryngology and Otology, 01.01.2019.

Research output: Contribution to journalReview article

Iqbal, M. S. ; Wilkinson, D. ; Tin, A. ; Bossi, P. ; Gradwell-Nelson, L. ; Kovarik, J. ; O'Hara, J. ; Kelly, C. / Cetuximab in the management of nasopharyngeal carcinoma - A narrative review. In: Journal of Laryngology and Otology. 2019.
@article{dcb1580a0d404be6be8860bae4ee6f53,
title = "Cetuximab in the management of nasopharyngeal carcinoma - A narrative review",
abstract = "BackgroundConcurrent chemotherapy with radiotherapy is the standard treatment for locoregionally advanced nasopharyngeal cancer. Cetuximab can be used in the treatment of head and neck squamous cell carcinoma. However, the randomised studies that led to approval for its use in this setting excluded nasopharyngeal cancer. In the context of limited data for the use of cetuximab in nasopharyngeal cancer in the medical literature, this review aimed to summarise the current evidence for its use in both primary and recurrent or metastatic disease.MethodA literature search was performed using the keywords 'nasopharyngeal neoplasm', 'cetuximab' and 'Erbitux'.ResultsTwenty studies were included. There were no randomised phase III trials, but there were nine phase II trials. The use of cetuximab in the treatment of nasopharyngeal carcinoma has been tested in various settings, including in combination with induction chemotherapy and concurrent chemoradiotherapy, and in the palliative setting.ConclusionThere is no evidence of benefit from the addition of cetuximab to standard management protocols, and there is some evidence of increased toxicity. There is more promise for its use in metastatic or locally recurrent settings. This review draws together the existing evidence and could provide a focus for future studies.",
keywords = "Cetuximab, Nasopharyngeal Carcinoma, Review",
author = "Iqbal, {M. S.} and D. Wilkinson and A. Tin and P. Bossi and L. Gradwell-Nelson and J. Kovarik and J. O'Hara and C. Kelly",
year = "2019",
month = "1",
day = "1",
doi = "10.1017/S0022215119001853",
language = "English",
journal = "Journal of Laryngology and Otology",
issn = "0022-2151",
publisher = "Cambridge University Press",

}

TY - JOUR

T1 - Cetuximab in the management of nasopharyngeal carcinoma - A narrative review

AU - Iqbal, M. S.

AU - Wilkinson, D.

AU - Tin, A.

AU - Bossi, P.

AU - Gradwell-Nelson, L.

AU - Kovarik, J.

AU - O'Hara, J.

AU - Kelly, C.

PY - 2019/1/1

Y1 - 2019/1/1

N2 - BackgroundConcurrent chemotherapy with radiotherapy is the standard treatment for locoregionally advanced nasopharyngeal cancer. Cetuximab can be used in the treatment of head and neck squamous cell carcinoma. However, the randomised studies that led to approval for its use in this setting excluded nasopharyngeal cancer. In the context of limited data for the use of cetuximab in nasopharyngeal cancer in the medical literature, this review aimed to summarise the current evidence for its use in both primary and recurrent or metastatic disease.MethodA literature search was performed using the keywords 'nasopharyngeal neoplasm', 'cetuximab' and 'Erbitux'.ResultsTwenty studies were included. There were no randomised phase III trials, but there were nine phase II trials. The use of cetuximab in the treatment of nasopharyngeal carcinoma has been tested in various settings, including in combination with induction chemotherapy and concurrent chemoradiotherapy, and in the palliative setting.ConclusionThere is no evidence of benefit from the addition of cetuximab to standard management protocols, and there is some evidence of increased toxicity. There is more promise for its use in metastatic or locally recurrent settings. This review draws together the existing evidence and could provide a focus for future studies.

AB - BackgroundConcurrent chemotherapy with radiotherapy is the standard treatment for locoregionally advanced nasopharyngeal cancer. Cetuximab can be used in the treatment of head and neck squamous cell carcinoma. However, the randomised studies that led to approval for its use in this setting excluded nasopharyngeal cancer. In the context of limited data for the use of cetuximab in nasopharyngeal cancer in the medical literature, this review aimed to summarise the current evidence for its use in both primary and recurrent or metastatic disease.MethodA literature search was performed using the keywords 'nasopharyngeal neoplasm', 'cetuximab' and 'Erbitux'.ResultsTwenty studies were included. There were no randomised phase III trials, but there were nine phase II trials. The use of cetuximab in the treatment of nasopharyngeal carcinoma has been tested in various settings, including in combination with induction chemotherapy and concurrent chemoradiotherapy, and in the palliative setting.ConclusionThere is no evidence of benefit from the addition of cetuximab to standard management protocols, and there is some evidence of increased toxicity. There is more promise for its use in metastatic or locally recurrent settings. This review draws together the existing evidence and could provide a focus for future studies.

KW - Cetuximab

KW - Nasopharyngeal Carcinoma

KW - Review

UR - http://www.scopus.com/inward/record.url?scp=85072127201&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85072127201&partnerID=8YFLogxK

U2 - 10.1017/S0022215119001853

DO - 10.1017/S0022215119001853

M3 - Review article

C2 - 31506113

AN - SCOPUS:85072127201

JO - Journal of Laryngology and Otology

JF - Journal of Laryngology and Otology

SN - 0022-2151

ER -